Jag Capital Management LLC Acquires 4,319 Shares of Natera, Inc. $NTRA

Jag Capital Management LLC grew its holdings in Natera, Inc. (NASDAQ:NTRA) by 5.3% during the first quarter, HoldingsChannel.com reports. The firm owned 85,091 shares of the medical research company’s stock after acquiring an additional 4,319 shares during the quarter. Natera makes up about 1.9% of Jag Capital Management LLC’s holdings, making the stock its 19th biggest holding. Jag Capital Management LLC’s holdings in Natera were worth $17,017,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in NTRA. Coatue Management LLC grew its holdings in shares of Natera by 1,446.1% in the fourth quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock worth $603,270,000 after purchasing an additional 2,463,008 shares during the last quarter. Wellington Management Group LLP boosted its position in Natera by 94.7% in the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock valued at $1,140,026,000 after buying an additional 2,420,263 shares during the period. Norges Bank purchased a new stake in Natera in the 4th quarter valued at about $372,398,000. JPMorgan Chase & Co. grew its stake in Natera by 10.5% in the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock worth $2,944,800,000 after acquiring an additional 1,225,420 shares in the last quarter. Finally, AQR Capital Management LLC grew its stake in Natera by 39.0% in the 3rd quarter. AQR Capital Management LLC now owns 2,400,065 shares of the medical research company’s stock worth $386,338,000 after acquiring an additional 673,315 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

NTRA has been the subject of several research analyst reports. Robert W. Baird set a $265.00 price target on shares of Natera in a research note on Friday, May 8th. William Blair started coverage on shares of Natera in a research note on Tuesday, April 14th. They set an “outperform” rating for the company. The Goldman Sachs Group started coverage on shares of Natera in a research note on Friday, June 5th. They set a “neutral” rating and a $245.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research report on Tuesday, April 21st. Finally, Guggenheim upped their price target on Natera from $270.00 to $290.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $267.83.

Natera Stock Performance

NASDAQ:NTRA opened at $269.83 on Friday. Natera, Inc. has a fifty-two week low of $131.81 and a fifty-two week high of $288.04. The company has a 50 day moving average price of $232.43 and a 200 day moving average price of $220.05. The stock has a market capitalization of $38.64 billion, a P/E ratio of -165.54 and a beta of 1.51.

Insider Buying and Selling

In related news, CEO Steven Leonard Chapman sold 41,124 shares of Natera stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $221.03, for a total value of $9,089,637.72. Following the completion of the transaction, the chief executive officer owned 108,743 shares in the company, valued at approximately $24,035,465.29. The trade was a 27.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Solomon Moshkevich sold 3,405 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $203.69, for a total transaction of $693,564.45. Following the completion of the transaction, the insider directly owned 142,295 shares of the company’s stock, valued at $28,984,068.55. This represents a 2.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 178,872 shares of company stock worth $39,627,696 over the last 90 days. 5.05% of the stock is owned by insiders.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.